Cannabis Use
Conditions
Keywords
youth, cannabis, education, health, prevention, marijuana
Brief summary
The Stanford Smart Talk Cannabis Awareness and Prevention Curriculum includes 5 lessons, each providing activities, online quiz games, and worksheets in addition to presentations, resources, and other materials aimed at addressing key factors associated with youth cannabis use, including changing adolescents' attitudes towards and misperceptions about cannabis; increasing their refusal skills to pulls of marketing and social media; reducing stress and depression which have been linked to cannabis initiation and use; improving coping skills; and decreasing intentions and actual use of all cannabis products. The aim of this study is to investigate the extent to which the curriculum changes students' intentions to use and actual use of cannabis.
Interventions
BEHAVIORALStanford Smart Talk Cannabis Awareness and Prevention curriculum
Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session curriculum administered in a school classroom setting.
Sponsors
Stanford University
National Institute on Drug Abuse (NIDA)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 20 Years
Healthy volunteers
Yes
Inclusion criteria
* Middle school and high school students receiving health education at schools participating in the study
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cannabis Use (Lifetime) | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assess lifetime cannabis use. This outcome measure assesses cannabis use. |
| Cannabis Use (Past 30 Days) | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assess cannabis use in the past 30 days. |
| Intention to Use Cannabis in the Future - Smoked Cannabis | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes). |
| Intention to Use Cannabis in the Future - Vaped Cannabis | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes). |
| Intention to Use Cannabis in the Future - Cannabis Edibles | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assessing participant intention to use cannabis in the future. Assessed on a Likert-scale (1 - Definitely not, 4 - Definitely yes). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cannabis Knowledge | Baseline and Post-intervention (approx. 3 days post-baseline) | Participants were asked 13 questions related to their knowledge of cannabis, resulting in an overall scale of 0 to 13, higher scores indicated greater knowledge. |
| Perceived Addictiveness and Harmfulness - Smoked Cannabis | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assessing participants' perceptions of cannabis addiction and harm. Assessed on a Likert-scale (1 - Not at all addictive/harmful, 5 - Extremely addictive/harmful). |
| Perceived Addictiveness and Harmfulness - Vaped Cannabis | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assessing participants' perceptions of cannabis addiction and harm. Assessed on a Likert-scale (1 - Not at all addictive/harmful, 5 - Extremely addictive/harmful). |
| Perceived Addictiveness and Harmfulness - Cannabis Edibles | Baseline, Post-intervention (approx. 3 days post-baseline), and 6-month Follow-up | Investigator-originated survey measures (questions) assessing participants' perceptions of cannabis addiction and harm. Assessed on a Likert-scale (1 - Not at all addictive/harmful, 5 - Extremely addictive/harmful). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORBonnie Halpern-Felsher, Ph.D.
Stanford University
Participant flow
Pre-assignment details
19 schools were assessed for eligibility. 11 were randomized to intervention or standard of care. Educators were considered to be enrolled only at those schools that received the intervention (they delivered the intervention to the students, and participated in post-intervention qualitative interviews focused on quality assurance and quality improvement).
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 14.0 years STANDARD_DEVIATION 0.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 18 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 115 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 51 Participants |
| Race (NIH/OMB) Black or African American | 19 Participants |
| Race (NIH/OMB) More than one race | 26 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 7 Participants |
| Race (NIH/OMB) White | 95 Participants |
| Region of Enrollment United States | 425 Participants |
| Sex/Gender, Customized Man | 78 Participants |
| Sex/Gender, Customized Non-binary/Gender Diverse | 9 Participants |
| Sex/Gender, Customized Unknown/Not Reported | 1 Participants |
| Sex/Gender, Customized Woman | 70 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 419 | 0 / 239 |
| other Total, other adverse events | 0 / 419 | 0 / 239 |
| serious Total, serious adverse events | 0 / 419 | 0 / 239 |
Outcome results
None listed